Using Semaglutide and Liraglutide to Help with Alcohol Problems
Author Information
Author(s): Lähteenvuo Markku MD PhD, Tiihonen Jari MD PhD, Solismaa Anssi MD PhD, Tanskanen Antti PhD, Mittendorfer-Rutz Ellenor PhD, Taipale Heidi PhD
Primary Institution: University of Eastern Finland
Hypothesis
Are glucagon-like peptide-1 receptor (GLP-1) agonists effective in the treatment of alcohol use disorder?
Conclusion
The use of semaglutide and liraglutide is associated with a significantly lower risk of hospitalization due to alcohol use disorder.
Supporting Evidence
- Individuals using semaglutide had a 36% lower risk of hospitalization due to alcohol use disorder.
- Liraglutide users had a 28% lower risk of hospitalization due to alcohol use disorder.
- The study followed participants for a median of 8.8 years.
Takeaway
This study found that two medications, semaglutide and liraglutide, can help people who have problems with alcohol by reducing their chances of needing to go to the hospital.
Methodology
This cohort study used nationwide registry data from Sweden to analyze hospitalization risks for individuals with alcohol use disorder during periods of GLP-1 agonist use versus nonuse.
Potential Biases
The study's design may introduce biases related to confounding factors.
Limitations
As an observational study, it can only establish associations, not causality.
Participant Demographics
The cohort included 63.5% male and 36.5% female individuals, with a mean age of 40.0 years.
Statistical Information
P-Value
0.64 for semaglutide, 0.72 for liraglutide
Confidence Interval
95% CI, 0.50-0.83 for semaglutide; 95% CI, 0.57-0.92 for liraglutide
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website